Patent application EP15183983A (EP), filed 2015-09-05
Publication number: EP3138579A1
Title: FUSION PROTEIN FOR USE IN THE TREATMENT OF A HEPATITIS B VIRUS INFECTION
Abstract: [0001]    The present invention relates to a fusion protein for use in the treatment and/or prevention of a hepatitis B virus infection comprising at least one hepatitis B PreS polypeptide or fragment thereof fused to at least one peptide consisting of an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 4.
IPC codes: A61K  39/    29            A I
A61K  39/    36            A I
A61P  31/    20            A I
C12N  15/    62            A I
Claims: number: 1
text: Fusion protein for use in the treatment and/or prevention of a hepatitis B virus infection comprising at least one hepatitis B PreS polypeptide or fragment thereof fused to at least one peptide consisting of an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and SEQ ID No. 4.
number: 2
text: Fusion protein for the use according to claim 1, wherein the amino acid sequence of the PreS polypeptide is at least 80% identical to SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID No. 11, SEQ ID No. 12 or SEQ ID No. 13.
number: 3
text: Fusion protein for the use according to claim 1 or 2, wherein the at least one peptide is fused to the N- and/or C-terminus of the PreS polypeptide.
number: 4
text: Fusion protein for the use according to any one of claims 1 to 3, wherein the fusion protein comprises an amino acid sequence which is at least 80% identical to SEQ ID No. 6.
number: 5
text: Fusion protein for the use according to any one of claims 1 to 4, wherein the hepatitis B virus infection is caused by a hepatitis B virus genotype A, B, C, D, E, F, G, H or a subtype thereof.
number: 6
text: Fusion protein for the use according to any one of claims 1 to 5, wherein the fusion protein is administered to an individual at least once in an amount of 0.01 µg/kg body weight to 5 mg/kg body weight, preferably 0.1 µg/kg body weight to 2 mg/kg body weight.
number: 7
text: Fusion protein for the use according to any one of claims 1 to 6, wherein the fusion protein is administered together with at least one adjuvant and/or pharmaceutical acceptable excipient.
Office action: search_report, dated 2017-03-08
Rejection reasons: novelty_epc_54
inventive_step_epc_56
Prior art cited: ref_id: WO9843670A2
ref_type: patent
severity: background
ref_id: WO9633739A1
ref_type: patent
severity: background
ref_id: WO9611711A1
ref_type: patent
severity: background
ref_id: US5057540A
ref_type: patent
severity: background
ref_id: EP0362279B1
ref_type: patent
severity: background
ref_id: - SAMBROOK ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOR LABORATORY PRESS
ref_type: npl
severity: background
ref_id: - AUSUBEL ET AL.: "Short Protocols in Molecular Biology", 1995, WILEY AND SONS
ref_type: npl
severity: background
ref_id: - ALTSCHUL SF ET AL., J. MOL. BI O1, vol. 215, 1990, pages 403 - 410
ref_type: npl
severity: background
ref_id: - SCHAEFER ET AL., WORLD J GASTROENTEROL, vol. 13, 2007, pages 14 - 21
ref_type: npl
severity: background
ref_id: - A. ROBINSON; M. P. CRANAGE; M. HUDSON: "Vaccine Protocols", 2003, HUMANA PRESS INC.
ref_type: npl
severity: background
ref_id: - NIESPODZIANA K ET AL., J ALLERGY CLIN IMMUNOL, vol. 127, 2011, pages 1562 - 70
ref_type: npl
severity: background
ref_id: - HAYER J ET AL., NUCLEIC ACIDS RES, 2012, pages 1022
ref_type: npl
severity: background
ref_id: WO2012168487A1
ref_type: patent
severity: background
ref_id: WO2009092612A1
ref_type: patent
severity: background
ref_id: - KATARZYNA NIESPODZIANA ET AL: "A hypoallergenic cat vaccine based on Fel d 1derived peptides fused to hepatitis B PreS", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 127, no. 6, 4 January 2011 (2011-01-04), pages 1562 - 1570.e6, XP028385498, ISSN: 0091-6749, [retrieved on 20110212], DOI: 10.1016/J.JACI.2011.02.004
ref_type: npl
severity: background
ref_id: - MARGARETE FOCKE-TEJKL ET AL: "Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 135, no. 5, 13 November 2014 (2014-11-13), AMSTERDAM, NL, pages 1207 - 1217.e11, XP055249930, ISSN: 0091-6749, DOI: 10.1016/j.jaci.2014.09.012
ref_type: npl
severity: background
ref_id: - HONG CHEN ET AL: "Optimisation of Prime-Boost Immunization in Mice Using Novel Protein-Based and Recombinant Vaccinia (Tiantan)-Based HBV Vaccine", PLOS ONE, vol. 7, no. 9, 6 September 2012 (2012-09-06), pages e43730, XP055250123, DOI: 10.1371/journal.pone.0043730
ref_type: npl
severity: background
ref_id: WO2009092612
ref_type: patent
severity: obviousness
ref_id: WO2012168487
ref_type: patent
severity: novelty_destroying
ref_id: - KATARZYNA NIESPODZIANA ET AL, "A hypoallergenic cat vaccine based on Fel d 1derived peptides fused to hepatitis B PreS", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 127, no. 6, doi:10.1016/J.JACI.2011.02.004, ISSN 0091-6749, (20110104), pages 1562 - 1570.e6, (20110212), XP028385498 [I] 1-7 * abstract * * page  1568, column  r, paragraph  1 * * page  1562, column  r, paragraph  2 * [Y] 1-7
ref_type: npl
severity: obviousness
ref_id: - MARGARETE FOCKE-TEJKL ET AL, "Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, AMSTERDAM, NL, (20141113), vol. 135, no. 5, doi:10.1016/j.jaci.2014.09.012, ISSN 0091-6749, pages 1207 - 1217.e11, XP055249930 [I] 1-7 * abstract * * page  1209, column  r, paragraph  l * [Y] 1-7
ref_type: npl
severity: obviousness
ref_id: - HONG CHEN ET AL, "Optimisation of Prime-Boost Immunization in Mice Using Novel Protein-Based and Recombinant Vaccinia (Tiantan)-Based HBV Vaccine", PLOS ONE, (20120906), vol. 7, no. 9, doi:10.1371/journal.pone.0043730, page e43730, XP055250123 [Y] 1-7 * abstract * * page  2, column  l, paragraphs  2-3 * * page  6, column  l, paragraph  1  - page  8, column  r, paragraph  3 *
ref_type: npl
severity: obviousness
Final disposition: pending (2017-03-08)